| Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL (NCT05296525) | Gamida Cell ltd | 2022-07-05 |
| A Phase I/II Study of AZD0466 as Monotherapy or in Combination With Anticancer Agents in Advanced Non-Hodgkin Lymphoma (NCT05205161) | AstraZeneca | 2022-07-05 |
| RADVAX™ for Relapsed/Refractory Non-Hodgkin Lymphoma: A Phase II Trial of Pembrolizumab + Low Dose Radiotherapy (NCT04827862) | Abramson Cancer Center at Penn Medicine | 2022-07-01 |
| Programmed Allogeneic CRISPR-edited T Cells Engineered to Express Anti-CD19 Chimeric Antigen Receptor (PACE CART19) in Patients With Relapsed Or Refractory CD19+ Leukemia and Lymphoma (NCT05037669) | University of Pennsylvania | 2022-07-01 |
| A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma (NCT05283720) | Genmab | 2022-06-14 |
| Safety, PK/PD, and Clinical Activity of KT-413 in Adult Patients with Relapsed or Refractory B-cell NHL (NCT05233033) | Kymera Therapeutics, Inc. | 2022-06-13 |
| Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation (NCT05005299) | Melbourne Health | 2022-06-08 |
| CD19.CAR-multiVSTs for Patients With CD19+ B-ALL or NHL Undergoing Related Allogeneic HSCT (CARMA) (NCT03768310) | Baylor College of Medicine | 2022-06-01 |
| Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory B-cell Malignancies (NCT05410041) | Beijing Boren Hospital | 2022-05-25 |
| A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors (NCT05528055) | Jiangsu Simcere Pharmaceutical Co., Ltd. | 2022-05-18 |
| GVM±R in Patients With Relapsed or Refractory Aggressive NHL (NCT05299164) | Institute of Hematology & Blood Diseases Hospital, China | 2022-05-15 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. (NCT04771572) | Newave Pharmaceutical Inc | 2022-05-08 |
| Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader (NCT05294731) | BeiGene | 2022-05-06 |
| A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma (NCT05171647) | Hoffmann-La Roche | 2022-04-25 |
| Triamcinolone Acetonide Injections in Primary Cutaneous Lymphoma Plaques With a Novel Needle-free Drug-delivery System. (NCT05106192) | Case Comprehensive Cancer Center | 2022-04-01 |
| Transplantation of Hematopoietic Stem Cells From HLA-compatible Donors in Patients With B-Cell Lymphoid Malignancies (NCT04684979) | Baptist Health South Florida | 2022-03-28 |
| Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma (NCT05169658) | University of Washington | 2022-03-23 |
| Improving Communication and Building a Stronger Medical Home Among Spanish-speaking Families (NCT05425992) | University of Colorado, Denver | 2022-03-17 |
| Long-Term Follow-up Study (NCT05332054) | Caribou Biosciences, Inc. | 2022-03-16 |
| Investigating Cognitive Impairment in Young Patients With Cancer Prospectively (NCT05840575) | Rigshospitalet, Denmark | 2022-03-01 |
| Duvelisib Following Chimeric Antigen Receptor T-Cell Therapy (NCT05044039) | Washington University School of Medicine | 2022-02-28 |
| Mobility and Physical Activity in Adolescent and Young Adult Cancer Patients or Survivors at Risk for Cardiovascular Morbidity and Frailty, The MOBILE AYA Study (NCT05169151) | M.D. Anderson Cancer Center | 2022-02-17 |
| A Study to Evaluate Activity, Safety and Tolerability of ZX-101A in Relapsed/Refractory Hematological Malignancies (NCT05269940) | Nanjing Zenshine Pharmaceuticals | 2022-02-17 |
| A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies (NCT05207670) | Genentech, Inc. | 2022-02-01 |
| Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma (NCT05253495) | New York Medical College | 2022-02-01 |
| A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell Lymphoma (NCT05200312) | The First Affiliated Hospital with Nanjing Medical University | 2022-02-01 |
| A Study of BTX-1188 in Subjects With Advanced Malignancies (NCT05144334) | Biotheryx, Inc. | 2022-01-24 |
| Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients (NCT05098613) | University of Colorado, Denver | 2021-12-21 |
| Orelabrutinib in Combination With Thiotepa in Refractory and Relapsed Primary CNS Lymphoma (NCT05021770) | Huiqiang Huang | 2021-12-01 |
| Social Health, Activity Behaviors, and Quality of Life Among Young Adult Cancer Survivors (NCT07259304) | University of Southern California | 2021-11-24 |
| Duvelisib in Combination With BMS-986345 in Lymphoid Malignancy (NCT05065866) | H. Lee Moffitt Cancer Center and Research Institute | 2021-11-18 |
| Two Step Haplo With Radiation Conditioning (NCT05031897) | Thomas Jefferson University | 2021-10-25 |
| A Phase I Study of ZN-d5 in Chinese Subjects With Non-Hodgkin Lymphoma (NCT05127811) | Zentera Therapeutics HK Limited | 2021-10-21 |
| In-Human CXCR4 Imaging of Hematologic and Solid Tumors Using [68Ga]-Pentixafor-PET (NCT05093335) | Memorial Sloan Kettering Cancer Center | 2021-10-01 |
| Radiation Dose Study for Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma (NCT05019976) | University of Chicago | 2021-09-30 |
| A Study Evaluating Safety, PK, and Efficacy of Tafasitamab and Parsaclisib in Participants With Relapsed/Refractory Non Hodgkin Lymphoma (R/R NHL) or Chronic Lymphocytic Leukemia (CLL) (NCT04809467) | Incyte Corporation | 2021-09-16 |
| Ex-vivo Primed Memory Donor Lymphocyte Infusion to Boost Anti-viral Immunity After T-cell Depleted HSCT (NCT05066958) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2021-09-16 |
| A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies (NCT05006716) | BeOne Medicines | 2021-09-13 |
| Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma (NCT05420493) | Chongqing Precision Biotech Co., Ltd | 2021-09-06 |
| Understanding the Risk of Blood Clots and Bleeding in Patients With Hematological Malignancies, HAT Study (NCT05053100) | Mayo Clinic | 2021-08-17 |
| Phase 3 Study of Zandelisib (ME-401) in Combination With Rituximab in Patients With iNHL - (COASTAL) (NCT04745832) | MEI Pharma, Inc. | 2021-08-13 |
| Wearable Sensors and Molecular Omics to Detect and Mitigate Cell Therapy Adverse Events (NCT05123001) | Stanford University | 2021-07-15 |
| Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma (NCT04739813) | National Cancer Institute (NCI) | 2021-07-09 |
| IIT2020-20-SHIRAZIP-WALK: Nature Walks (NCT04896580) | Cedars-Sinai Medical Center | 2021-06-21 |
| Geriatric Optimization Plan to Improve Survival in Older Adult Allogeneic Hematopoietic Cell Transplant Candidates, OTIS Study (NCT05972577) | Ohio State University Comprehensive Cancer Center | 2021-06-11 |
| CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER) (NCT04637763) | Caribou Biosciences, Inc. | 2021-05-26 |
| TisaGenlecleucel in Elderly Patients With First-Relapsed or Primary Refractory Aggressive B-cell Non-Hodgkin Lymphoma (NCT04161118) | University of Cologne | 2021-05-12 |
| huCART19-IL18 in CD19+ Cancers (NCT04684563) | University of Pennsylvania | 2021-05-06 |
| The Registry of Oncology Outcomes Associated With Testing and Treatment (NCT04028479) | Taproot Health | 2021-05-05 |
| Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies (NCT04732845) | Benjamin Tomlinson | 2021-04-26 |
| Gentulizumab in Patients With Advanced Solid Malignancies and Non-Hodgkin Lymphoma (NCT05221385) | Changchun GeneScience Pharmaceutical Co., Ltd. | 2021-04-12 |
| AlloSCT for Malignant and Non-malignant Hematologic Diseases Utilizing Alpha/Beta T Cell and CD19+ B Cell Depletion (NCT04099966) | Mitchell Cairo | 2021-04-01 |
| AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NCT04673617) | Artiva Biotherapeutics, Inc. | 2021-03-29 |
| Study of ADG106 In Combination With PD-1 Antibody In Advanced or Metastatic Solid Tumors and/or Non Hodgkin Lymphoma (NCT04775680) | Adagene (Suzhou) Limited | 2021-03-11 |
| APR-246 in Combination With Acalabrutinib or Venetoclax Based Therapy in Subjects With R/R Non Hodgkin Lymphomas (NHL) (NCT04419389) | Aprea Therapeutics | 2021-03-02 |
| Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With R/R DLBCL or R/R CLL (NCT04502394) | Kartos Therapeutics, Inc. | 2021-02-23 |
| Methods of T Cell Depletion Trial (MoTD) (NCT04888741) | University of Birmingham | 2021-02-22 |
| Effects of Prebiotics on Gut Microbiome in Patients Undergoing HSCT (NCT04629430) | University of Virginia | 2021-02-19 |
| Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies (NCT04504708) | Hangzhou Zenshine Pharmaceuticals Co., Ltd. | 2021-02-17 |
| A Study of KB-0742 in Participants With Relapsed or Refractory Solid Tumors Including Platinum Resistant High Grade Serous Ovarian Cancer (HGSOC) (NCT04718675) | Kronos Bio | 2021-02-08 |
| Study of 68GaNOTA-Anti-MMR-VHH2 in Oncological Lesions, Cardiovascular Atherosclerosis, Syndrome With Abnormal Immune Activation and sarcoïdosis (NCT04758650) | Universitair Ziekenhuis Brussel | 2021-01-26 |
| Cardiac Rehabilitation for Patients Receiving Radiation Therapy for Thoracic Cancers (NCT04072393) | Washington University School of Medicine | 2021-01-15 |
| Heart Rate Variability, Vagus Nerve and Cancer (NCT04718610) | Centre Hospitalier Henri Duffaut - Avignon | 2021-01-12 |
| Diet, Physical Activity and Body Composition Changes During R-CHOP (NCT04293900) | George Washington University | 2021-01-01 |
| A Study of CTA30X Cell Injection in Patients With Relapsed or Refractory CD19-positive B-line Hematological Malignancies (NCT04689204) | He Huang | 2020-12-29 |
| A Post-treatment Program to Identify and Manage Complications Related to Oncology or Hematology Treatments in Cancer Survivors. (NCT04671693) | Centre Leon Berard | 2020-12-24 |
| 'Re-Priming' RT After Incomplete Response to CAR-T in R/R NHL (NCT04601831) | University of Texas Southwestern Medical Center | 2020-12-23 |
| Cardiovascular Reserve Evaluation in Survivors of Transplant, CREST Study (NCT04537871) | City of Hope Medical Center | 2020-11-18 |
| Study of GS-0189 (Formerly FSI-189) as Monotherapy and in Combination With Rituximab in Participants With Relapsed/Refractory Non-Hodgkin Lymphoma (NCT04502706) | Gilead Sciences | 2020-11-17 |
| Phase I Clinical Study of GNC-038 in Patients With Non-Hodgkin's Lymphoma or Acute Lymphoblastic Leukemia (NCT04606433) | Sichuan Baili Pharmaceutical Co., Ltd. | 2020-11-04 |
| Irradiated Donor Cells Following Stem Cell Transplant in Controlling Cancer in Patients With Hematologic Malignancies (NCT03272633) | Rutgers, The State University of New Jersey | 2020-10-26 |
| The clonoSEQ® Watch Registry (NCT04545333) | Adaptive Biotechnologies | 2020-10-13 |
| Phase 1 First in Human Study of ZN-d5 as a Single Agent (NCT04500587) | K-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc. | 2020-10-13 |
| Ibrutinib With Methotrexate and Temozolomide for Patients With Newly Diagnosed Primary CNS Lymphoma (NCT04514393) | Huiqiang Huang | 2020-10-10 |
| A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity (NCT04150913) | Marcela V. Maus, M.D.,Ph.D. | 2020-10-01 |
| Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors (NCT03935282) | Wake Forest University Health Sciences | 2020-10-01 |
| A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies (NCT04543305) | Prelude Therapeutics | 2020-09-28 |
| SARS-CoV-2 Donor-Recipient Immunity Transfer (NCT04666025) | City of Hope Medical Center | 2020-09-23 |
| Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants with Relapsed, Refractory, or Newly Diagnosed Cancers (NCT04553692) | IGM Biosciences, Inc. | 2020-09-23 |
| FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL (NCT04555811) | Masonic Cancer Center, University of Minnesota | 2020-09-22 |
| CPI-613 in Combination With Bendamustine in Patients With Relapsed/Refractory T-Cell Non-Hodgkin Lymphoma (NCT04217317) | Wake Forest University Health Sciences | 2020-09-16 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma (NCT04545762) | C. Babis Andreadis | 2020-09-11 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Study of Feasibility and Safety of UCD19 Chimeric Antigen Receptor (CAR) T Cells in Adult Subjects With Relapsed/Refractory (R/R) B-Cell Non-Hodgkin's Lymphoma (B-NHL) (NCT04240808) | University of Colorado, Denver | 2020-07-17 |
| Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer (NCT04478123) | Memorial Sloan Kettering Cancer Center | 2020-07-14 |
| Managing Pain and Symptom Burden Caused by Chemotherapy in People With Myeloma or Lymphoma (NCT04459416) | Memorial Sloan Kettering Cancer Center | 2020-06-30 |
| A Phase I Study of LP-108 in Patients With Relapsed or Refractory B-cell Lymphoma (NCT04356846) | The First Affiliated Hospital with Nanjing Medical University | 2020-05-01 |
| Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor (NCT04337606) | Chinese PLA General Hospital | 2020-04-04 |
| TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia (NCT04323657) | TCR2 Therapeutics | 2020-03-27 |
| Adapting Multiple Behavior Interventions That Effectively Improve Cancer Survivor Health Cancer Survivor Health (NCT04000880) | University of Alabama at Birmingham | 2020-03-04 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma (NCT07041827) | The Netherlands Cancer Institute | 2020-02-01 |
| A Study to Assess Safety and Efficacy of CHO-H01 as a Single Agent/Combined With Lenalidomide in Subjects With Refractory or Relapsed Non-Hodgkin's Lymphoma (NCT05950165) | Cho Pharma Inc. | 2020-01-15 |
| A Clinical Study to Evaluate Pharmacokinetics, Safety, and Tolerability of Abexinostat in Chinese Patients (NCT04024696) | Xynomic Pharmaceuticals, Inc. | 2020-01-08 |
| A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy (NCT04227015) | He Huang | 2020-01-08 |
| Non-invasive Evaluation of Lymphoma Patients Based on Artificial Intelligence and PET/MRI (NCT04154228) | Tel-Aviv Sourasky Medical Center | 2019-12-10 |
| Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (NCT04060277) | City of Hope Medical Center | 2019-11-27 |
| The Clinical Study of CD20 CAR-T Cells in Patients With Relapsed and Refractory B Cell Non-Hodgkin Lymphoma (NCT04169932) | Shanghai Longyao Biotechnology Inc., Ltd. | 2019-11-22 |
| Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. (NCT03886649) | Swiss Cancer Institute | 2019-11-04 |
| Study of CD19 Specific Chimeric Antigen Receptor Positive T Cells (CAR-T) in ALL and NHL (NCT04206943) | Acibadem University | 2019-10-12 |